Cessation Therapeutics, Inc.

San Jose, CA · Founded 2022 · CIK 0001926434 · Biotech · Private

High-affinity anti-nicotine monoclonal antibodies developed through novel vaccine design for smoking cessation

cessationtherapeutics.com →
Grants
$422K
2 awards
Sector median: 1
Raised
$6.8M
2 Form D · Apr 2024
30 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development of Therapeutic Anti-Nicotine Monoclonal Antibodies through Trivalent Vaccine Design$211,174
Federal grantDepartment of Health and Human Services · Phase I · Development of Therapeutic Anti-Nicotine Monoclonal Antibodies through Trivalent Vaccine Design$211,174
Private capital raisedForm D · SEC$5,755,000
Private capital raisedForm D · SEC$1,000,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1173MediSix Therapeutics, Inc.—$35M
1174ISOThrive Inc.—$17M
1175Unleash Immuno Oncolytics, Inc.—$3.0M
1176Cessation Therapeutics, Inc.—$6.8M
1177Dnalite Therapeutics, Inc.—$5.6M
1178Xenon Pharmaceuticals——
1179Pagari Life Science Corp.—$678K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 8 related persons
  • Andrew BarrettExecutive Officer
  • Daniel FineDirector
  • David GenecovDirector
  • John HarkeyDirector · Executive Officer
  • Mark PearsonDirector · Executive Officer
  • Eric RasmussenExecutive Officer
  • Jay ShepardDirector
  • Sharon TetlowDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.